Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

New acne treatments show promise as alternatives to traditional therapies.

This study provided 18 evidence-based recommendations for managing acne vulgaris, strongly endorsing treatments like benzoyl peroxide, topical retinoids, and oral isotretinoin for severe cases, and issued conditional recommendations for therapies like salicylic acid and spironolactone, while offering good practice statements on combining treatment methods.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.

This review summarizes recent research on the skin microbiome's role in acne development and how antibiotic treatments affect skin microbes, but it reports no new clinical results.

This study discusses the importance of careful dermatological care for transgender youth receiving hormonal therapies, cautioning that acne treatments can interfere with hormone replacement therapy and emphasizing the need for a collaborative interdisciplinary approach to support both acne management and overall well-being.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this chemical investigation, cyclospongiaquinone 1 from the sponge Verongula cf. rigida showed strong steroid 5α-reductase inhibitory activity, comparable to that of finasteride.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study found that a combination of ciclosporin and Miglyol 812 was effective in treating sebaceous adenitis in rabbits, with significant improvement in skin condition and hair regrowth.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.